Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 69


PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.

Wartenberg M, Centeno I, Haemmig S, Vassella E, Zlobec I, Galván JA, Neuenschwander M, Schlup C, Gloor B, Lugli A, Perren A, Karamitopoulou E.

Eur J Cancer. 2016 Sep;65:80-90. doi: 10.1016/j.ejca.2016.06.013. Epub 2016 Jul 29.


DAPK loss in colon cancer tumor buds: implications for migration capacity of disseminating tumor cells.

Ivanovska J, Zlobec I, Forster S, Karamitopoulou E, Dawson H, Koelzer VH, Agaimy A, Garreis F, Söder S, Laqua W, Lugli A, Hartmann A, Rau TT, Schneider-Stock R.

Oncotarget. 2015 Nov 3;6(34):36774-88. doi: 10.18632/oncotarget.4908.


Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.

Koelzer VH, Huber B, Mele V, Iezzi G, Trippel M, Karamitopoulou E, Zlobec I, Lugli A.

Hum Pathol. 2015 Nov;46(11):1573-81. doi: 10.1016/j.humpath.2015.07.010. Epub 2015 Jul 29.


Loss of tapasin correlates with diminished CD8(+) T-cell immunity and prognosis in colorectal cancer.

Sokol L, Koelzer VH, Rau TT, Karamitopoulou E, Zlobec I, Lugli A.

J Transl Med. 2015 Aug 27;13:279. doi: 10.1186/s12967-015-0647-1.


Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer.

Galván JA, Zlobec I, Wartenberg M, Lugli A, Gloor B, Perren A, Karamitopoulou E.

Br J Cancer. 2015 Jun 9;112(12):1944-50. doi: 10.1038/bjc.2015.177. Epub 2015 May 19.


Warthin's tumor of the larynx: a very rare case and systematic review of the literature.

Nisa L, Landis BN, Salmina C, Ailianou A, Karamitopoulou E, Giger R.

J Otolaryngol Head Neck Surg. 2015 May 12;44:16. doi: 10.1186/s40463-015-0067-5. Review.


Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study.

Koelzer VH, Herrmann P, Zlobec I, Karamitopoulou E, Lugli A, Stein U.

BMC Cancer. 2015 Mar 21;15:160. doi: 10.1186/s12885-015-1150-z.


HIPK2 deficiency causes chromosomal instability by cytokinesis failure and increases tumorigenicity.

Valente D, Bossi G, Moncada A, Tornincasa M, Indelicato S, Piscuoglio S, Karamitopoulou ED, Bartolazzi A, Pierantoni GM, Fusco A, Soddu S, Rinaldo C.

Oncotarget. 2015 Apr 30;6(12):10320-34.


Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.

Koelzer VH, Dawson H, Andersson E, Karamitopoulou E, Masucci GV, Lugli A, Zlobec I.

Transl Res. 2015 Aug;166(2):207-17. doi: 10.1016/j.trsl.2015.02.008. Epub 2015 Mar 4.


Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin.

Karamitopoulou E, Zlobec I, Koelzer VH, Langer R, Dawson H, Lugli A.

Histopathology. 2015 Oct;67(4):464-73. doi: 10.1111/his.12665. Epub 2015 Mar 23.


TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.

Galván JA, Helbling M, Koelzer VH, Tschan MP, Berger MD, Hädrich M, Schnüriger B, Karamitopoulou E, Dawson H, Inderbitzin D, Lugli A, Zlobec I.

Oncotarget. 2015 Jan 20;6(2):874-85.


Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.

Dawson H, Grundmann S, Koelzer VH, Galván JA, Kirsch R, Karamitopoulou E, Lugli A, Inderbitzin D, Zlobec I.

Histopathology. 2015 Apr;66(5):715-25. doi: 10.1111/his.12603. Epub 2014 Dec 23.


Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.

Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC.

Mod Pathol. 2015 Mar;28(3):391-402. doi: 10.1038/modpathol.2014.113. Epub 2014 Sep 12.


Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.

Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R.

Am J Surg Pathol. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255.


Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients.

Helbling M, Lukesch A, Haimovici A, Karamitopoulou E, Berger MD, Hädrich M, Mallaev M, Schnüriger B, Koelzer VH, Dawson H, Borner M, Langer R, Rosenberg R, Nitsche U, Inderbitzin D, Lugli A, Tschan M, Zlobec I.

Oncotarget. 2014 Jul 15;5(13):4671-82.


Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis.

Karamitopoulou E, Shoni M, Theoharides TC.

Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):213-20.


HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L.

Neoplasia. 2014 Jan;16(1):31-42.


Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).

Karamitopoulou E, Zlobec I, Gloor B, Kondi-Pafiti A, Lugli A, Perren A.

J Transl Med. 2013 Dec 14;11:311. doi: 10.1186/1479-5876-11-311.


Pretreatment with sevoflurane attenuates direct lung injury.

Kalimeris K, Zerva A, Matsota P, Nomikos T, Fragopoulou E, Politi AN, Karamitopoulou E, Kostopanagiotou G.

Minerva Anestesiol. 2014 Jun;80(6):635-44. Epub 2013 Dec 4.

Items per page

Supplemental Content

Loading ...
Support Center